A principal pathological feature of Alzheimer's disease is the deposition of Al3 in brain parenchyma (Glenner and Wong, 1984; Masters et al., 1985) . Al3, an -4 kDa polypeptide, is derived from larger type I integral membrane glycoproteins, termed the amyloid precursor proteins (APP) (Kang et al., 1987; Kitaguchi et al., 1988; Ponte et al., 1988; Tanzi et al., 1988; Golde et al., 1990; K&rig et al., 1992) . APP is a member of a family of homologous amyloid precursor-like proteins (APLPs), including APLPl (Wasco et al., 1992) and APLP2 (Sprecher et al., 1993; Wasco et al., 1993; Slunt et al., 1994) . Although the members of this gene family share considerable homology in the amino-and carboxyl-terminal domains, the APLPs differ from APP by the absence of the Al3 region.
At present, APLP2 is the best characterized member of APLPs. Like APP APLP2 is encoded by several mRNAs derived by alternative splicing (Wasco et al., 1993; Sandbrink et al., 1994; Slunt et al., 1994) . Both APP and APLP2 are expressed in brain and peripheral tissues (Wasco et al., 1993; Slunt et al., 1994) , and in situ hybridization studies disclose similarities in the distributions of APP and APLP2 mRNAs in mouse (Slunt et al., 1994) and human (Wasco et al., 1993) CNS. Finally, APLP2 matures through the same unusual secretory/cleavage pathway as APP (Slunt et al., 1994) . However, in contrast to APP-695 and APP-7511770, APLP2-751 is a substrate for modification by a single CS GAG chain .
In this study, we report on the distribution of APLP2 in the rodent nervous system using newly generated antibodies specific for APLP2. Consistent with previous in situ hybridization studies (Slunt et al., 1994) , our investigations with the APLPZspecific antibodies revealed that APLP2 is expressed in a variety of regions, including cerebral cortex, hippocampus, and thalamus. Confocal microscopy revealed prominent colocalization of APLP2 with MAP-2, a postsynaptic marker, in cortex and hippocampus. Moreover, APLP2 mRNA is highly expressed in sensory neurons in the olfactory epithelium, and the encoded polypeptide is abundant in olfactory sensory axons, and axon terminals in glomeruli. In contrast to its predominant postsynaptic localization in neurons in cortex and hippocampus, APLP2 is present in both pre-and postsynaptic compartments in the ol-factory bulb. Notably, mRNA encoding CS GAG-modified forms of APLP2 are highly represented in the olfactory epithehum, and CS GAG modified forms of APLP2 accumulate in the olfactory bulb. Since olfactory sensory neurons are continually turned over, axons of newly generated neurons must establish synaptic connections with neurons in the olfactory bulb in adult life. Taken together with the view that CS proteoglycans play an important role in regulating cell migration and neuronal outgrowth (for review, see Wight et al., 1992) , the unique localization of APLP2 in olfactory sensory axons and glomemli is consistent with the notion that this protein may play an important role in axonal pathfinding and/or synaptogenesis.
Materials and Methods
Antibodies. Ab369 is a polyclonal antibody raised against the entire cytoplasmic domain (residues 645-694) of APP-695 (Buxbaum et al., 1990) , and was kindly provided by Dr. Samuel Gandy (Cornell University Medical College, New York). c-Myc-modified APLP2 polypeptides were immunoprecipitated using polyclonal antiserum Myc-I (provided by Dr. Philip Wong, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore), raised against the synthetic peptide MEQKLISEEDLN (Lee et al., 1993) .
To generate polyclonal APLP2-specific antibody CT12, a synthetic peptide corresponding to the C-terminal 12 amino acids (residues 740-75 1) of mouse APLP2-75 1 with an additional cysteine at the N-terminus (CNPTYKYLEQMQI) was coupled to maleimide-activated keyhole limpet hemocyanin (Imject, Pierce Chemical Co., Rockford, IL). The conjugate was purified by gel filtration and subsequently injected into New Zealand White rabbits. Polyclonal antibodies D2-I and D2-II were raised in two separate rabbits using full. length mouse APLP2-75 1 synthesized in Sf9 cells as the antigen, as described previously .
Purijcation of CT12, 02-J and 02-U antibodies. For immunocytochemical studies, we prepared an IgG fraction of CT12 antibody using a Protein A agarose affinity column (Pierce Chemical Co., Rockford, IL). D2-I and D2-II antibodies were affinity purified on a column containing a glutathione S-transferase (GST)-APLP2 fusion protein. Briefly, sequences that encode residues 562-681 of mouse APLP2-751 (Slunt et al., 1994) were generated by PCR and subcloned into plasmid pGEX-2T (Smith and Johnson, 1988) . The resulting plasmid, pGEXAAPLP2, encodes a fusion of GST with a 120 amino acid region of APLP2-751 which occurs immediately N-terminal to the transmembrane domain. The GST fusion protein (GSTAAPLP2) was expressed in bacteria and immobilized onto glutathione agarose beads as described (Smith and Johnson, 1988) . For affinity purification, an IgG fraction of the D2-I or DZII antiserum was incubated at 4°C for 16 hr with glutathione agarose beads containing bound GSTAAPLP2. The beads were washed twice in a buffer containing 50 mu Tris-HCl (pH 7.5) and 0.3 M NaCl. Bound antibodies were eluted with 2 ml of 100 mu glycine-HCl (pH 2.5) and neutralized.
Plasmid construction. To generate pEF695, an expression construct containing the mouse APP695 cDNA, plasmid pFLAPP (provided by Dr. Bruce T. Lamb, Department of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore) was incubated in a polymerase chain reaction with sense primer 5'-CCGCTC-GAGACGATGCTGCCCAGCTTGG-3', antisense primer 5 '-CCGCTC-GAGGCTTAGTTCTGCATTTGCTC-3' and a third primer 5'-CGCC-TGGACCTGGAGAATTACATCATCGC-3' in order to modify the internal X/z01 site. The PCR product was digested with XhoI and the APP cDNA fragment was ligated to an unique Sal1 site in a modified pEFBOS vector (Mizushima and Nagata, 1990) . Plasmids pSVAPLP1 and pSVAPLP2 which contain the mouse APLPl and APLP2-75.1 cDNA, respectively, placed downstream of the SV40 promoter/enhancer were generated as follows. Sequences encoding mouse APLPl were excised from a Bluescript vector (Wasco et al., 1992;  kindly provided by Dr. Wilma Wasco, Harvard Medical School) and inserted in a pUC 19-based vector from p77OSP . The APLP2 cDNA insert was isolated from plasmid pD2 (Slunt et al., 1994) , and ligated to a vector molecule derived from plasmid p77OSP .
Transfection, immunoprecipitation, and Western blot analysis. COS-1 cells, an African green monkey kidney line, were transiently transfected in 60 mm plates with 10 pg of CsCl-purified plasmid DNA using a high-efficiency calcium phosphate method (Chen and Okayama, 1987) . Thirty-six hours after transfection, cells were labeled with 200 l&i/ml 35S-methionine (Du Pont NEN, Wilmington, DE) for 3 hr in Dulbecco's modified Eagle medium lacking methionine and supplemented with 1% dialyzed fetal calf serum. Detergent lysates and conditioned medium prepared from labeled cells were subject to immunoprecipitation analisis as described (Sisodia et al., 1996; Slunt et al., 1994) :CT12, D2-I, and D2-II antibodies were used at 1:2500 dilution for Western blot analysis of lysates prepared from cells transiently expressing APP, APLPl, or APLP2.
In situ hybridization. Sequences that encode residues 568-681 of mouse APLP2 were cloned into Bluescript KS+ (Slunt et al., 1994) and used as templates to generate sense or antisense 33P-labeled riboprobes using a RNA transcription kit (Stratagene, La Jolla, CA (Chirgwin et al., 1979) . Reverse-transcribed RNA was used in PCR to amplify alternatively spliced APLPZ mRNA. The primer pair SD2, S'-CCGCTCGAGGAACAGCGAGCG-3' (encoding amino acids 567-570 of APLP2, and containing an X/z01 site at its 5' end) and antisense primer AsD2, S'-CCGGAAlTCATTGCTGCTCAAACTGAAAT-CC-3' (complementary to sequences encoding amino acids 675481 of APLP2-751 and containing an EcoRI site at its 5' end) was used to analyze the presence of alternatively spliced transcripts which encode a 12 amino acid peptide, DTQPELYHPMKK, primer pair SKPI, 5'-GTGCTGCCCTCAGACAAAG-3' (encoding amino acids 202-207 of APLP2) and antisense primer AsD2 (above) was used to analyze alternatively spliced transcripts which encode the KPI domain and/or the 12 amino acid peptide (see above). In order to identify PCR products generated from the four different mRNA isofoxms of APLP2, cloned cDNA corresponding to APLP2-694, APLP2-751, or APLP2-763 were used as templates in parallel PCR reactions. The PCR products were separated on 1.3% agarose or 3% NuSieve GTG agarose (FMC Bioproducts, Rockland, ME) and visualized by ethidium bromide staining.
Zmmunocytochemistry. C57/B 16 mice (Jackson Laboratories, Bar Harbor, Maine) or adult Sprague-Dawley rats were administered lethal doses of the anesthetic Xylaket (25% ketamine, 2.5% xylazine in 15% ethanol, 0.9% saline) and perfused intracardially with PBS, followed by 4% freshly depolymerized paraformaldehyde in 0.1 M PBS. The olfactory epithelium was dissected following removal of craniofacial skeletal tissue and fascia and postfixed in 4% paraformaldehyde in PBS for 2 hr. Olfactory bulbs were dissected and postfixed as above. After fixation, dissected tissue was equilibrated and cryoprotected in 10% sucrose in PBS at 4"C, then transferred to plastic molds and embedded in OCT medium (Tissue Tek, Miles, Inc., Elkhart, IN) on dry ice. Tissue was stored at -20°C until cryostat sections (10 pm) were cut onto gelatinsubbed glass slides and stored at -20°C.
For immunocytochemical analysis, sections were first blocked for 1 hr in PBS containing 10% normal goat serum, 1% bovine serum albumin and oermeabilized in 0.1% Triton X-100 in PBS. Primarv antibodies were-incubated with sections overnight at 4°C in 4% no&al goat serum. CT12 IgG was used at 6 kg/ml, and control reactions were performed by preincubating an equivalent aliquot of antibody overnight et al. -APLPP in Olfactory System at 4°C with 60 pg/ml of CT12 peptide. D2-I and D2-II antibodies were affinity purified on a GST-fusion protein matrix (see above) and used at 0.5 p,g/ml. For control reactions, the appropriate dilution of antibody was preincubated overnight with 25 pg of GST-fusion protein bound to matrix and used as indicated above. Primary antibodies were recognized and subsequently visualized using an avidin-biotin-peroxidase kit (Vector, Burlingame, CA) according to the manufacturer's instructions and visualized with diaminobenzidine.
Sections were viewed and photographed using a Zeiss Axiophot microscope and camera and images were processed and compiled using an AGFA color scanner and image analysis system.
Laser scanning confocal microscopy. Forty micrometer thick paraformaldehyde-fixed brain sections were double immunolabeled using a combination of oolvclonal anti-APLP2 suecific antibody, D2-I (at 1:500), with moiocfonal anti-synaptophys;n (at 1:20) or monoclonal anti-MAP-2 antibodies (at 1:20) (anti-synaptophysin and anti-MAP-2 antibodies were from Boehringer-Mannheim Labs, Indianapolis, IN). Bound antibodies were subsequently reacted with a FITC-conjugated horse anti-mouse IgG (1:75) and biotinylated goat anti-rabbit IgG secondarv antibodies (1:lOO). followed bv avidin-Texas red (1:lOO) (Vectar, Burlingame, Ck). tie double stained sections were transferred to SuperFrost plus slides (Fisher, Tustin, CA) and mounted under glass coverslips with anti-fading media containing 4% n-propyl gallate (Sigma, St. Louis, MO). Sections were examined using the Bio-Rad MRC-600 laser scanning microscope mounted on an Zeiss Axiovert 35 microscope and optical Z-sections 0.5 p,rn in thickness were collected and stored as described (Masliah et al., 1993) .
Preparation ofbruin exrracrs. Adult Sprague-Dawley rats were deeply anesthetized and perfused transcardially with PBS. The brain was then removed and different regions were dissected quickly and frozen at -70°C. Soluble and membrane protein extracts were prepared as described (Blackstone et al., 1992) . Briefly, tissues were homogenized with a Brinkmann Polytron in 10 volumes of ice-cold 10 mu Tris-HCl (pH 7.4) containing 10% (wt/vol) sucrose and protease inhibitors (20 pg/ml each of leupeptin, pepstatin, antipain, and chymostatin, 0.2 U/ml aprotinin, 10 mu benzamidine, 0.1 mu PMSF, 1 mu EGTA, and 1 mu EDTA). The homogenate was centrifuged at 1000 X g for 10 min to remove nuclei and-cell debris, and the resulting supernatant fraction was centrifuged at 114.000 X ,e for 20 min at 4°C. The supernatant fraction (S2)Yfrom the high speed centrifugation containing soluble proteins was saved. The pellet fraction (P2) containing membrane proteins was washed twice by resuspension in homogenization buffer (lacking sucrose), centrifuged at 114,000 X g for 20 min and finally resuspended in homogenization buffer. Glycerol was added to both S2 and P2 fractions to a final concentration of 20% and the extracts were stored at -70°C.
Chondroirinase digestion. Ten microgram aliquots of the S2 fraction prepared from olfactory bulb and hippocampus were digested with 5 mU of protease-free chondroitinase ABC (Seikagaku America, Inc., Rockville, MD) in 100 mu Tris-HCl (pH 8.0) and 30 mu sodium acetate for 1 hr at 37°C. As a positive control for chondroitinase digestions, we used serum-free conditioned medium prepared from a CHO cell line, B2, that constitutively expresses mouse APLP2-751 (Thinakaran and and which secretes soluble CS GAG-modified APLP2 derivatives.
Results

Biochemical characterization of anti-APLP2 antibodies
In an earlier report (Slunt et al., 1994) , we noted that several widely utilized antibodies raised against APP are highly crossreactive with APLP2, a result due in large part to the significant sequence homology between the two proteins. In the present study, we report on the characterization of APLPZspecific antibodies and the use of these reagents in immunocytochemical and biochemical studies of the distribution of APLP2 in the rodent nervous system. To assess the specificity of antibodies D2-I and D2-II, raised against fulllength mouse APLP2-751 or CT12 antisera, generated against the C-terminal 12 amino acids of APLP2, we performed immunoblot analyses of lysates prepared from COS-1 cells transiently transfected with expression plasmids encoding mouse APP-695, mouse APLPl, or mouse APLP2-751. To document that each of the transgene-derived polypeptides were expressed in transiently transfected cells, we immunoprecipitated each species from 35S-methionine-labeled detergent lysates using an an-, tibody Ab369, raised against the entire cytoplasmic tail (residues 645-694) of APP-695 (Buxbaum et al., 1990) . We anticipated that Ab369 would recognize APLPl based on our earlier studies documenting that Ab369 recognizes APLP2 (Slunt et al., 1994) . Ab369 immunoprecipitated low levels of endogenously expressed -110, -115, and -130 kDa APPIAPLP polypeptides from extracts of COS-1 cells transfected with the expression plasmid which lacked a cDNA (Fig. lA, lane 1) . As expected, COS-1 cells transfected with plasmid pEF695 overexpressed -110 kDa APP-695 (Fig. lA, lane 2) . Furthermore, cells transfected with plasmids pSVAPLP1 or pSVAPLP2 expressed -100 kDa APLPl or -120 kDa APLP2 polypeptides, respectively (Fig. lA, lanes 3 and 4, respectively) ; the heterogeneous smear of polypeptides extending from -125 kDa to -200 kDa in lane 4 represents CS GAG-modified forms of APLP2-75 1 (see below, Thinakaran and Sisodia, 1994) . Antibody D2-I, raised against full-length mouse APLP2-75 1 detected low levels of endogenously synthesized -110 and 115 kDa polypeptides in COS-1 cells (Fig. lC, lane 1) and high levels of -115-200 kDa forms of APLP2 from extracts of cells transfected with APLP2-75 1 cDNA ( Fig. 1 C, lane 4) . Similarly, antibody D2-II recognized high levels of -115-200 kDa forms of APLP2 in extracts of cells expressing APLP2-751 (Fig. lC,  lane 8) . Neither D2-I nor DZII antibodies detected transiently expressed mouse APP-695 or APLPl (Fig. lC, lanes 2,3 and 6,7, respectively). Antibody CT12, raised against the C-terminal 12 amino acids of APLP2, also detected low levels of endogenously synthesized -110 and 115 kDa polypeptides in COS-1 cells (Fig. lC, lane 9 ) and an -115 kDa form of APLP2 in extracts of cells overexpressing APLPZ (Fig. lC, lane 12) . Moreover, CT12 failed to detect either APP-695 or APLPl (Fig.  lC, lanes 10 and 11, respectively) . The heterogeneity of the mature forms of APLP2 (Fig. lC, lanes 4, 8) is the result of addition of variable-length CS GAG chains to APLP2 core proteins . The apparent failure of CT12 antibody to detect the heterogeneous APLP2 species is due to the insensitivity of this reagent relative to the D2-I and D2-II antibodies. Thus, these results unambiguously document that antibodies D2-I, DZII, and CT12 specifically recognize APLP2, but not its homologous proteins, APP and APLPl.
Localization of APLP2 in cortical and hippocampal neurons Consistent with our earlier in situ hybridization analyses of APLP2 mRNA expression (Slunt et al., 1994) , immunocytochemical mapping with antibodies D2-I, D2-II, and CT12 verified that APLP2 is expressed in neuronal populations in many regions of mouse brain, including cerebral cortex, hippocampus, and thalamus. To examine the subcellular distribution of APLP2 in neuronal populations in cortex and hippocampus, we doublestained sections with D2-I and synaptophysin, a marker for presynaptic boutons, or for D2-I and MAP-2, a dendritic cytoskeleton-associated marker. Sections were analyzed by laser scanning confocal microscopy. In the hippocampus, predominant APLP2 immunoreactivity (IR) was observed in apical dendrites (Fig. 2b) , structures which were strongly stained with antibodies specific to the dendritic marker, MAP-2 (Fig. 2a,c) . Parallel colocalization studies of APLP2 IR (Fig. 2e ) and synaptophysin IR (Fig. 2d) again revealed prominent localization of APLP2 in apical dendrites, but some overlap in IR was evident in the neu- ropil, as well (Fig. 2f) . Similarly, in cortex, we observed an essentially identical colocalization pattern with APLP2 and MAP-2 antibodies in dendrites, with modest overlap in staining using APLP2 and synaptophysin antibodies in the neuropil (data not shown). As part of our effort to map the distributions of APLP2 in brain, we noted an interesting distribution of this molecule in the rodent olfactory system. Hence, we have focused our attention on the distribution of APLP2 mRNA and proteins in cells within this circuit.
Expression of APLPZ mRNA in olfactory epithelium To examine the cellular expression of APLP2 mRNA in the olfactory epithelium, we used in situ hybridization analysis. We generated 33P-labeled riboprobes complementary to the sequences that encode a llO-amino acid stretch that immediately precedes the transmembrane domain of APLP2; this sequence of APLP2 is highly divergent from an analogous region of APP (Slunt et al., 1994) . In Figure 3 , we demonstrate that mRNAs encoding APLP2 are abundantly expressed throughout the re-KPI TM gion of the olfactory epithelium that contains sensory neurons and sustentacular cells. On the basis of earlier studies which documented that the primary APLP2 transcript undergoes alternate splicing (Sprecher et al., 1993; Wasco et al., 1993; Sandbrink et al., 1994; Slunt et al., 1994) , we carried out RT-PCR analysis of mRNA prepared from olfactory epithelium. The alternatively spliced APLP2 transcripts encode APLP2 polypeptides of 694, 706, 751, or 763 amino acids (Fig. 4) . The 751 and 763 isoforms contain a domain homologous to the Kunitz protease inhibitors, while the 694 and 706 forms lack this region. Moreover, the 706 and 763 forms contain an additional 12 amino acid sequence encoded by an alternatively spliced exon. We recently documented that APLP2-75 1 undergoes modification by the addition of CS GAG at a single site, serine-614 . The amino acid sequence near the CS GAG attachment site is ENEGSGMAEQ (residues 61 O-6 19 of the APLP2-75 1 isoform). Notably, the additional 12 amino acid sequence in the APLP2-706 and APLP2-763 isoforms is inserted immediately upstream of the CS attachment site. The sequence of the insert and residues flanking the CS GAG attachment site is ENEDTQPE-LYHPMKKGSGMAEQ. Indeed, we have recently demonstrated that the APLP2-763 isoform fails to be modified by CS GAG (Thinakaran et al., 1995) suggesting that the insert disrupts the optimal recognition sequence for CS GAG addition. For example, in transiently transfected COS-1 cells, APLP2-751 is synthesized as an -120 kDa polypeptide, and matures into heterogeneous CS GAG-modified polypeptides of -130-200 kDa (Fig. 5A, lane 1) . In contrast, APLP2-763 is synthesized as a -120 kDa molecule, and matures into a homogeneous polypeptide of -130 kDa (Fig. 5A, lane 2) . Furthermore, immunoprecipitation of soluble APLPZderivatives from conditioned media also revealed that APLP2-75 1 is secreted as heterogeneous population of polypeptides of -100-150 kDa, while APLP2-763 is secreted as a -100 kDa polypeptide (Fig. 5A, lanes 3 and 4) . These results demonstrate that unlike APLP2-75 1, the APLP2-763 isoform fails to undergo modification by CS GAG. Thus, we conclude that only two 7f the alternatively spliced isoforms of APLP2, APLP2-694, and APLP2-75 1 are substrates for modification by the addition of CS GAG chains.
In order to determine whether APLP2 mRNA expressed in olfactory epithelium contains alternatively spliced sequence encoding the 12 amino acid peptide, we performed RT-PCR analysis with primers that flank the sequence and we expected two products. We performed a parallel analysis of RNA isolated from mouse brain. Equal amounts of RNA from each tissue were reverse transcribed, and the resulting cDNA subject to PCR for an identical number of cycles. We demonstrate that In brain, the vast majority of PCR product is the longer form and thus contains sequences which encode the 12 amino acid peptide (Fig.  5B, lane 4) . These results are essentially indistinguishable from quantitative RT-PCR studies of mRNA from rat cortex, hippocampus, and cerebellum in which transcripts encoding the 12 amino acid peptide represented 87%, 92%, and 95%, respectively, of total APLP2 mRNA in these tissues (Sandbrink et al., 1994) . On the other hand, the shorter PCR product is the predominant species in olfactory epithelium and hence lacks sequences that encode the peptide (Fig. 5B, lane 3) . To distinguish between APLP2 mRNA that contained both, or either the 12 amino acid peptide and KPI sequences, we performed RT-PCR analysis with a sense primer upstream of the KPI domain and an antisense primer downstream of the insertion site. PCR analysis revealed that the vast majority of APLP2 mRNA expressed in olfactory epithelium does not contain the sequences encoding the KPI domain (Fig. 5C, lane l) , whereas, the majority of the APLP2 mRNA expressed in brain contains this sequence (Fig.  5C, lane 2) . Thus, we conclude that the CS GAG modified isoforms, APLP2-694 and APLP2-751, are the preponderant APLP2 isoforms expressed in olfactory epithelium.
Immunocytochemical localization of APLPZ in the rodent olfactory system We performed immunocytochemical analysis of the distribution of APLP2 in the olfactory system of mouse and rat using the APLPZspecific antibodies described above. For immunocyto- chemical analysis of the mouse olfactory system, we affinity purified D2-I and DZII antibodies on a bacterially expressed fusion protein (GSTAAPLP2) that contained a 120 amino acid region of APLP2-751 which occurs immediately N-terminal to the transmembrane domain. The affinity purified antibodies detect both full-length and soluble (C-terminal truncated) APLP2 derivatives (G. Thinakaran and S. Sisodia, unpublished observations) , similar to those detected with unpurified APLP2 antisera . Immunocytochemical analysis of the mouse olfactory epithelium with affinity purified D2-I antibody revealed remarkable APLP2 IR in the sensory axons of olfactory receptor cells that are arranged in parallel fiber bundles and destined for the olfactory bulb (Fig. 6A) ; an essentially indistinguishable pattern of IR was obtained with antibody D2-II (Fig. 6C) . We demonstrated that the D2-I labeled structures are axon bundles by demonstrating cclocalization with the neuron-specific Class III P-tubulin monoclonal antibody, TuJl (Lee et al., 1990 ) (data not shown). Moreover, immunostaining patterns obtained with D2-I and D2-II antibodies were fully competable by prior incubation of the antibodies with the GSTA-APLP2 fusion protein (Fig. 6B,D) . Finally, we stained parallel sections with CT12 antisera, raised against the C-terminal 12 amino acids of APLP2 and which only recognize full-length APLP2 and its membrane-bound metabolites. As was observed with the D2-I and DZII antibodies, CT12 antiserum strongly stained the sensory axon bundles (Fig. 6E ) in the olfactory epithelium. Immunostaining was competable by prior incubation of the CT12 antiserum with CT12 peptide (Fig. 6F) . Given the strong staining in the sensory axon bundles in the olfactory ep-et al. l APLP2 in Olfactory System Figure 6 . APLP2 IR in mouse olfactory epithelium; 10 pm sections of olfactory neuroepithelium were examined immunohistochemically for APLP2 IR using affinity purified antibodies D2-I (A), DZII (C), and CT12 antisera (E). In all cases, only light APLP2 IR was detected in the olfactory receptor neurons (ORN). However, APLP2 IR was highly enriched in afferent axons (Ax) projecting to the olfactory bulb. APLP2 IR was abolished by preincubation of D2-I and D2-II antibodies with GSTAAPLPZ fusion protein (B and D) and CT12 antisera with immunizing peptide (F).
ithelium, we anticipated that APLP2 would also be localized to and granule cells, along with scattered APLP2 IR throughout the the terminal fields of the sensory afferents in the olfactory bulb.
neuropil of the external plexiform layer. Indeed, the glomeruli Using antibody D2-I, we show remarkable APLP2 IR in the were also strongly stained with DZII antibody and CT12 antiglomeruli of the olfactory bulb (Fig. 7A) . In addition, fine serum (Fig. 7 ,C and E, respectively). Moreover, staining in the APLP2 IR is seen in dendrites and cell bodies of mitral, tufted olfactory bulb by all three antibodies was competable with re- Figure 7 . APLP2 IR in mouse olfactory bulb; 10 pm sections of olfactory bulb were examined immunohistochemically for APLP2 IR using affinity purified antibodies D2-I (A), D2-II (C), and CT12 antisera (E). APLPZ IR was detected primarily in glomeruli (Gr) and mitral cells of the olfactory bulb, where axons from the neuroepithelium terminate and synapse. APLP2 IR was abolished by preincubation of D2 antibodies with GSTAAPLP2 fusion protein (B and D) and CT12 antisera with immunizing peptide (F).
spective antigens (Fig. 7B, 0, F, respectively) . Taken together idence that APLP2 and/or its metabolites are being specifically with our observation that antibodies against nonoverlapping epirecognized by each of the antibodies in situ. topes of APLP2 recognize an essentially indistinguishable set of To demonstrate that the pattern of immunostaining in mice structures in the olfactory system (i.e., in sensory axon bundles detected with the APLP2 antibodies was conserved in another and glomeruli), the competition studies provide compelling evrodent species, we immunostained sections of rat olfactory ep- Figure 8 . APLP2 IR in rat olfactory epithelium and bulb. A, A cross-section of rat olfactory epithelium (UE) and olfactory bulb (OBu) was examined for APLP2 expression using affinity punfied D2-I antibodies. Axons bundles (&) are clearly seen underlying the olfactory receptor neuron layer (ORN) and bundles of axons (arrow) are seen projecting through the cribiform plate (CP) into the glomemlar layer (CT) of the olfactory bulb. B, Higher power view of APLP2 IR in axons projecting through the cribiform plate into the glomerular layer. C, Higher power view of APLP2 IR in the glomerular layer.
ithelium and olfactory bulb with affinity purified antibody D2-I. A low power view of a cross-section through the olfactory epithelium and bulb shows strong staining of the sensory axons and glomeruli (Fig. 8A) . A higher power view illuminates coursing of D2-I immunoreactive sensory axon bundles from the epithelium through the cribiform plate towards the olfactory bulb (Fig. 8B ). Finally, a higher power view of the glomeruli shows strong D2-1 IR in this structure (Fig. 8C) . In order to define the subcellular localization of APLP2 in the glomeruli, we double-stained sections of the olfactory bulb with D2-I and synaptophysin, or for D2-I and MAP-2, and analyzed optical sections by laser scanning confocal microscopy. As expected, synaptophysin IR was present both in the terminal fields of the olfactory sensory afferents within the glomeruli and the incoming fiber tracts (Fig. 9d) . Costaining with the APLP2-specific antibody, D2-I, revealed conspicuous colocalization in structures stained with synaptophysin antibodies (Fig. 9ef) . On the other hand, MAP-2 antibody stained structures contained primarily in the external plexiform layer with negligible staining in the glomeruli (Fig. 90) . Similar to our observations in cortex and hippocampus. APLP2 IR strongly colocalized with MAP-2 immunoreactive structures in the external plexiform layer (Fig.  SC) . Nevertheless, it is clear that APLP2 IR extended into the glomeruli, a region which was essentially devoid of MAP-2 IR (Fig. 9b,c) .
Characterization of APLPZ proteoglycan in olfactoc bulb
Analysis of APLP2 mRNA in the olfactory epithelium (Fig.  .5&C ) strongly suggested that the encoded isoforms would be substrates for CS GAG addition. To assess the level of CS GAG modification of APLP2 in the olfactory system, we used D2-II antiserum in Western blot analysis of membrane-bound and soluble extracts prepared from olfactory bulb. a region which is enriched in APLP2 IR (see above). The D2-II antibody is specific for APLP2 (see Fig. 1 ). Immunoblot analysis of membrane fractions from whole brain, cortex, hippocampus, cerebellum, and spinal cord (Fig. lOA, lanes 1. 3-6 , respectively) revealed the presence of discrete APLP2-related species of -95 kDa, -100 kDa, and -115 kDa. On the other hand. D2-II recognized the -95 kDa, -100 kDa. and -115 kDa species and a heterogeneous pattern of polypeptides with apparent molecular weight of -120-160 kDa range in the olfactory bulb (Fig. lOA, lane  2) . We suggest that the membrane-bound APLP2 forms in the olfactory bulb sample that migrate between the -120-l 60 kDa (Fig. lOA, lane 2) represent accumulated CS GAG-modified species synthesized by olfactory receptor neurons and transported to the olfactory bulb. Moreover, our results are fully consistent with the earlier RT-PCR analysis in which we demonstrate that the vast majority of APLP2 mRNA in the olfactory epithelium encodes isoforms postulated to undergo CS GAG modification while brain primarily expresses APLP2 mRNA encoding the CS GAG inhibitory 12 amino acid peptide (see Fig. 5&C ). To confirm that accumulated APLP2 in the olfactory bulb was indeed modified by CS GAG. we treated the soluble fraction (S2) with chondroitinase ABC and subject the resulting preparations to immunoblot analysis with antibody D2-II. Soluble APLP2 derivatives in the S2 fraction from olfactory bulb migrates as a doublet of -85 kDa and -105 kDa and a heterogeneous species between -90-l 15 kDa (Fig. lOB, lane 1) . Chondroitinase ABC treatment of the S2 fraction converted the heterogeneous population of molecules to fairly discrete band that overlaps the -85 kDa species with little change in the levels of the -105 kDa species (Fig. lOB, lane 2) . Thus. we argue that the heterogeneity of the -90-l 15 kDa APLP2-related molecules in the S2 fraction is the result of CS GAG modification of a C-terminally truncated APLP2 core protein of -85 kDa. In contrast. the APLP2 forms in the S2 fraction from hippocampus appear as -85 kDa and -105 kDa species (Fig. lOB, lane 3) which, as expected. are insensitive to digestion with chondroitinase ABC (Fig. lOB, lane  4) . Finally, as a control for chondroitinase digestions. we prepared conditioned medium from CHO cells that constitutively express APLP2-75 1. As we previously documented : soluble APLP2-751 derivatives secreted by CHO cells migrate as a smear between -120-150 kDa (Fig.  lOB, lane 5) and these forms are fully sensitive to chondroitinase A Figure 10 . Expression of CS GAGmodified APLP2 in the olfactory system. A, Tbe P2 fraction (10 kg per lane) from whole brain, olfactory bulb, cortex, hippocampus, cerebellum, and spinal cord were fractionated by SDS-PAGE and subject to immunoblotting with APLP2-specific antibody, D2-II. Arrowhead indicates the APLPZ proteoglycan expressed in the olfactory bulb. B, The S2 fraction (10 kg) prepared from olfactory bulb and hippocampus, or an aliquot of conditioned medium prepared from CHO cells stably expressing mouse APLP2-75 1 were incubated at 37°C in the presence (+) or absence (-) of chondroitinase ABC. After digestion, the samples were fractionated by SDS-PAGE and immunoblotted using APLP2 antibody, D2-II. Tbe position of the chondroitinase-sensitive -90-120 kDa APLP2 species are marked by a bracket. Note that following chondroitinase digestion of soluble APLP2 forms from olfactorv bulb, a marked increase in the amobnt of -85 kDa APLP2 polypeptide (marked by an arrowhead) is observed with little change in the -105 kDa APLP2 polypeptide (marked by an asterisks).
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1 2 3 4 digestion, resulting in the production of a discrete species of -105 kDa (Fig. lo& lane 6 ). Discussion APP, the precursor of the A@ peptide, is a member of a family of closely related transmembraue glycoproteins that includes APLPl and APLPZ (Wasco et al., 1992 (Wasco et al., , 1993 Sprecher et al., 1993; Slunt et al., 1994) . At present, APLP2 is the best characterized member of the APLPs. APLP2 mRNAs are expressed in most, if not all, neuronal populations in the CNS and at high levels in peripheral tissues (Wasco et al., 1993; Slunt et al., 1994) . However, it is likely that the distribution of APLP2 in the CNS may show significant differences as compared to the mRNA expression patterns observed using in situ hybridization, particularly since APLP2, like APP Sisodia et al., 1993) , is transported in axons by the rapid anterograde component (G. Thinakaran and S. Sisodia, unpublished observations) . Furthermore, it is conceivable that differences in proteolytic processing and/or secretion of APLP2 between cell types may lead to differential accumulation of the precursor isoforms and its derivatives. Immunocytochemical methods have been used to study the distribution of APP in CNS (Card et al., 1988; Shivers et al., 1988; Kawarabayashi et al., 1991; Martin et al., 1991; Imaizumi et al., 1993; Okuda et al., 1994; Ouimet et al., 1994; Trapp and Hauer, 1994) but because antibodies raised against independent epitopes of APP cross-react with APLP2 (Slunt et al., 1994) , it is quite likely that the distributions of APP IR described in a variety of reports, including our own (Martin et al., 1991) reflect IR to APP, APLP2, and perhaps APLPl, as well. To define the distribution of APLP2 in the CNS, we generated a series of antibodies against nonoverlapping epitopes of mouse APLP2. Western blot analyses of lysates pre- 
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pared from COS-1 cells transiently transfected with cDNA encoding each of the known members of the APP family of proteins revealed that the APLP2 antibodies D2-I and DZ-II and CT12 specifically recognize APLP2. Previous in situ hybridization studies have shown that APLP2 is ubiquitously expressed in CNS. Indeed, our present immunocytochemical investigations confirm the in situ results, and in addition revealed that the preponderant subcellular localization of APLP2 in neurons of the cortex and hippocampus is in postsynaptic elements. Most provocative is our finding that APLP2, synthesized in sensory neurons of the olfactory epithelium, is enriched in sensory axons and sensory axon terminals in the glomeruli. In the olfactory bulb, colocalization studies of APLP2 with markers of synaptic (synaptophysin) or dendritic (MAP-2) structures reveal that APLP2 is present in presynaptic sites in the glomeruli as well as in postsynaptic elements in the outer plexiform layer.
Although speculative, we suggest that the unique distributions of APLP2 to sensory afferents and terminals may be linked to its generalized role in process formation or pathfinding, and connectivity. Olfactory sensory neurons are the only neuronal population in the adult mammalian CNS which are continuously renewed from a population of mitotic precursors, with replacement of neurons in the olfactory epithelium occurring every 4-6 weeks (Graziadei and Monti Graziadei, 1979) . Hence, axonal outgrowth from newly born sensory neurons towards the olfactory bulb is a process that requires molecular clues involved in guidance, adhesion, and synaptogenesis. We recently demonstrated that APLP2 is a substrate for modification by the addition of CS GAG chains . Altematively-spliced mRNA encoding isoforms of APLP2 (APLP2-706 and APLP2-763) that do not undergo modification by CS GAG (Thi-nakaran et al., 1995) are the predominantly expressed in cortex, hippocampus, and cerebellum (Sandbrink et al., 1994) , an observation we have now confirmed by biochemical analysis with our newly generated antibodies. However, the APLP2 isoforms which undergo CS GAG modification (APLP2-694 and APLPZ 75 1) are selectively expressed in olfactory epithelium. Although CS proteoglycans expressed by non-neuronal cells along pathways of axon outgrowth in developing retina (Brittis et al., 1992) and cerebellum (Friedlander et al., 1994) have been shown to repel axons, little is known regarding the role(s) of CS proteoglycans expressed intrinsically by neurons. Some studies, however have implicated a role for CS proteoglycans expressed on surfaces of neurons during development; in cerebellum, a CS proteoglycan of -250 kDa core protein (6B4 proteoglycan) is expressed in Purkinje cells, Golgi cells, deep cerebellar neurons, and brainstem nuclei and enriched in the mossy fibers during the outgrowth and maturation phases (Maeda et al., 1992) . We suggest that CS-modified APLP2 may play similar roles in axonal growth and synaptic maturation in the olfactory system.
